MedTrace Logo

Opioids and Esophageal Function

NCT01012960 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2011-12-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate if opioid-induced effects on the pharynx and esophagus is centrally or peripherally mediated.

Conditions

  • Pharyngeal Dysfunction
  • Esophageal Dysfunction

Interventions

DRUG

methylnaltrexone

0,15 mg/kg sc ( subcutaneously)once per volunteer

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Region Örebro County

    lead OTHER

Principal Investigators

  • Magnus Wattwil, MD · University Hospital Örebro

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01012960 on ClinicalTrials.gov